A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment

BACKGROUND: ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial. OBJECTIVE: The aim of this study was to present primary results of a Phase 3, double-blind, ADS-5102 trial (INROADS) for walking speed. METHODS: Adult participants with MS a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jeffrey A, Cameron, Michelle H, Goldman, Myla D, Goodman, Andrew D, Miller, Aaron E, Rollins, Anne, Llorens, Lily, Patni, Rajiv, Elfont, Robert, Johnson, Reed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978468/
https://www.ncbi.nlm.nih.gov/pubmed/34449295
http://dx.doi.org/10.1177/13524585211035333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978468/
https://www.ncbi.nlm.nih.gov/pubmed/34449295
http://dx.doi.org/10.1177/13524585211035333

Ejemplares similares